Ponatinib (AP24534)

目录号：S1490

Molecular Weight(MW): 532.56

Ponatinib (AP24534)是一种新型有效的多靶点抑制剂，在无细胞试验中作用于Abl，PDGFRα，VEGFR2，FGFR1和Src，IC50分别为0.37 nM，1.1 nM，1.5 nM，2.2 nM和5.4 nM。

规格

价格

库存

购买数量

10mM/1mL In DMSO	RMB 819.31	现货
10mg	RMB 903.01	现货
50mg	RMB 3034.48	现货
200mg	RMB 7959.08	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献83篇：

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(4):431-443

PubMed: 31543464 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14329

PubMed: 25970250 ( click the link to review the publication )

Cancer Cell, 2014, 26(2):207-21

PubMed: 25065853 ( click the link to review the publication )

Cancer Cell, 2012, 22(5):656-67

PubMed: 23153538 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-019-04022-x

PubMed: 31901955 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2020, 1864(4):129507

PubMed: 31881245 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2779

PubMed: 31515463 ( click the link to review the publication )

Leukemia, 2019, 33(8):1964-1977

PubMed: 30842608 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Protein Cell, 2019, 10(3):161-177

PubMed: 29667003 ( click the link to review the publication )

Br J Cancer, 2019, 120(6):612-620

PubMed: 30792533 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):1985-1996

PubMed: 31308077 ( click the link to review the publication )

FEBS J, 2019, 286(22):4443-4472

PubMed: 31155838 ( click the link to review the publication )

Front Oncol, 2019, 9:103

PubMed: 30931252 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

Cell Cycle, 2019, 18(18):2307-2322

PubMed: 31349760 ( click the link to review the publication )
Transl Oncol, 2019, 12(9):1221-1228

PubMed: 31276961 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Exp Dermatol, 2019, 10.1111/exd.14010

PubMed: 31338879 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2019, 46(2):126-136

PubMed: 30251267 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Sci Adv, 2018, 4(11):eaau0731

PubMed: 30417093 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(8):1932-1943

PubMed: 29440177 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1405-1415

PubMed: 29695637 ( click the link to review the publication )

Respir Res, 2018, 19(1):120

PubMed: 29921306 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncotarget, 2018, 9(100):37352-37366

PubMed: 30647837 ( click the link to review the publication )

Oncotarget, 2018, 9(65):32496-32506

PubMed: 30197758 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):8

PubMed: 28069043 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-17-0008

PubMed: 28500237 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10-:2130-2143

PubMed: 28751539 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Sci Rep, 2017, 7(1-:5519

PubMed: 28717217 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(6):1455-1467

PubMed: 27733071 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15219

PubMed: 29123157 ( click the link to review the publication )

Gut, 2016, 10.1136/gutjnl-2015-310382

PubMed: 26953272 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1273-1281

PubMed: 27068398 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )
Cancer Sci, 2016, 107(2):140-8

PubMed: 26583567 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Tumour Biol, 2016, 37(2):2365-78

PubMed: 26373734 ( click the link to review the publication )

Oncotarget, 2016, 7(47):78083-78094

PubMed: 27801667 ( click the link to review the publication )

Genes Chromosomes Cancer, 2016, 55(1):60-8

PubMed: 26391436 ( click the link to review the publication )

Oncotarget, 2016, 7(31-:50161-50179

PubMed: 27367030 ( click the link to review the publication )

Sci Transl Med, 2015, 7(298):298ra119

PubMed: 26223302 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Leukemia, 2015, 29(5)

PubMed: 25394714 ( click the link to review the publication )

Leukemia, 2015, 29(12):2390-2

PubMed: 26108694 ( click the link to review the publication )

J Med Chem, 2015, 58(23):9228-37

PubMed: 26562217 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Toxicol Sci, 2015, 143(1):147-55

PubMed: 25304212 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120841

PubMed: 25803811 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(2):133-44

PubMed: 24463606 ( click the link to review the publication )

Sci Transl Med, 2014, 6(261):261ra152

PubMed: 25378644 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Genome Biol, 2014, 15(8):428

PubMed: 25315765 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(9):1316-23

PubMed: 25122427 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2092-103

PubMed: 24436473 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 10.1073/pnas.1321173111

PubMed: 24550512 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2315-27

PubMed: 25053825 ( click the link to review the publication )

Structure, 2014, 22(12):1764-74

PubMed: 25465127 ( click the link to review the publication )
Oncol Rep, 2014, 31(4):1605-12

PubMed: 24481648 ( click the link to review the publication )

Thrombo Res, 2014, 135(1):155-60

PubMed: 25527332 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 446(1):54-60

PubMed: 24565842 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

Harvard University, 2014, Rachel Grace Liao

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2013, 19(6):1422-32

PubMed: 23319824 ( click the link to review the publication )

Cancer Res, 2013, 73(16):5195-205

PubMed: 23786770 ( click the link to review the publication )

Neoplasia, 2013, 15(8):975-88

PubMed: 23908597 ( click the link to review the publication )

Curr Cancer Drug Targets, 2012, 12(5):505-21

PubMed: 22483156 ( click the link to review the publication )

Exp Hematol, 2012, 41(4):335-45.e3

PubMed: 23287417 ( click the link to review the publication )

Mol Genet Metab, 2010, 100(4):309-15

PubMed: 20554235 ( click the link to review the publication )

产品安全说明书

Bcr-Abl抑制剂选择性比较

生物活性

产品描述

Ponatinib (AP24534)是一种新型有效的多靶点抑制剂，在无细胞试验中作用于Abl，PDGFRα，VEGFR2，FGFR1和Src，IC50分别为0.37 nM，1.1 nM，1.5 nM，2.2 nM和5.4 nM。

靶点

Abl ^[1] (Cell-free assay)	PDGFRα ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)	FGFR1 ^[1] (Cell-free assay)	c-Src ^[1] (Cell-free assay)	点击更多
0.37 nM	1.1 nM	1.5 nM	2.2 nM	5.4 nM	点击更多

体外研究

Ponatinib是有效的可用于口服的多靶点激酶抑制剂，作用于野生型细胞,及T315I 突变细胞IC50分别为1.2和8.8nM。^[1] Ponatinib抑制Ba/F3衍生细胞系的增殖。^[2] Ponatinib作用于表达野生型或T315I突变型BCR-ABL的CML细胞系，有效抑制BCR-ABL调节的信号。Ponatinib阻断在细胞瘤筛选时产生抗性突变。^[3] Ponatinib也抑制VEGFR和FGFR家族激酶，在体外抑制FLT3, KIT, FGFR1,和PDGFRa激酶活性时IC50分别为13, 13, 2, 和1 nM.^[4]Ponatinib抑制全部4种RTKs磷酸化，存在剂量依赖性，IC50值为0.3到20 nM。然而，Ponatinib抑制表达野生型FLT3的RS4;11细胞时IC50>100 nM。

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	NH\MSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTBwMECwNFAxODN3OTFOwG0>	MUjTRW5ITVJ?
MV-4-11	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLnTWM2OD1yLkCwNFA6PTZizszN	MmT0V2FPT0WU
MEG-01	NX;NcHgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUe0WnZJUUN3ME2wMlAxODF{ODFOwG0>	NGXXRppUSU6JRWK=
LAMA-84	MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XScGlEPTB;MD6wNFAyPjVizszN	M{LzT3NCVkeHUh?=
CGTH-W-1	MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVH0b3hGUUN3ME2wMlAxOTZ7IN88US=>	MlXGV2FPT0WU
KASUMI-1	M1vlSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37zUGlEPTB;MD6wNFIyPyEQvF2=	NWDPcmRPW0GQR1XS
BE-13	NV\t[GtxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTBwMECyOVkh\|ryP	MknUV2FPT0WU
CTV-1	NHPQSlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jFcWlEPTB;MD6wNFUzOSEQvF2=	Mke4V2FPT0WU
NKM-1	MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorITWM2OD1yLkCwOlU2KM7:TR?=	M4rRbHNCVkeHUh?=
MONO-MAC-6	MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETKZXNKSzVyPUCuNFA5OzdizszN	NE\DelBUSU6JRWK=
A204	M4XzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4q5ZmlEPTB;MD6wNVIyQCEQvF2=	M1zzPXNCVkeHUh?=
GDM-1	M3TNWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTBwMEG4N\|Mh\|ryP	MYfTRW5ITVJ?
AN3-CA	NXnJVFdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3VS2dYUUN3ME2wMlAyQDd\|IN88US=>	MVjTRW5ITVJ?
BL-70	NED1d\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2f3UmlEPTB;MD6wNlE6QSEQvF2=	NFnOcmlUSU6JRWK=
Daudi	Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnznTWM2OD1yLkCyOVM4KM7:TR?=	NWfvOZFDW0GQR1XS
KU812	NGjKNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDYTWM2OD1yLkCyPFQ5KM7:TR?=	MWDTRW5ITVJ?
KG-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwMEOyPVQh\|ryP	MoPPV2FPT0WU
DOHH-2	MlXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37aOmlEPTB;MD6wOFgxOyEQvF2=	NVH3b4dsW0GQR1XS
HuO9	NXjWXWd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVe3bm5vUUN3ME2wMlA2PDR6IN88US=>	MWjTRW5ITVJ?
EB2	NHLpZ5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIn5O3BKSzVyPUCuNFU2PzZizszN	M1nvPXNCVkeHUh?=
G-402	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV74RmVXUUN3ME2wMlA3OzRzIN88US=>	M2LSfHNCVkeHUh?=
SU-DHL-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYK4O\|RwUUN3ME2wMlA3Ozd7IN88US=>	MYXTRW5ITVJ?
NCI-H719	NIexXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUWxeVVNUUN3ME2wMlA4QDh6IN88US=>	NV64d4RQW0GQR1XS
MLMA	M4Xlbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHjNZNKSzVyPUCuNFkxPiEQvF2=	MoPJV2FPT0WU
KM12	M4Hpdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMEm3N\|ch\|ryP	MX7TRW5ITVJ?
SUP-T1	NVH5UIt7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWq5PJFtUUN3ME2wMlA6QTh{IN88US=>	MonZV2FPT0WU
MZ1-PC	M2T4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnER3VuUUN3ME2wMlEyOzN4IN88US=>	NGThNo1USU6JRWK=
MFE-296	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTBwMUG4N\|kh\|ryP	Ml\VV2FPT0WU
ALL-PO	NYnqNZJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7oTWM2OD1yLkGyOFQ{KM7:TR?=	M{\HU3NCVkeHUh?=
GB-1	MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXnWVRKSzVyPUCuNVI2OTJizszN	NEf0R2JUSU6JRWK=
SIG-M5	MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTBwMUOzO{DPxE1?	NFvobmVUSU6JRWK=
P30-OHK	NEjRc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfQPHZOUUN3ME2wMlE2Pjd{IN88US=>	MV;TRW5ITVJ?
NCI-H716	NX7IeGJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwMU[yOlYh\|ryP	NWP0fGRtW0GQR1XS
MPP-89	M4PETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33BeGlEPTB;MD6xOlk{OyEQvF2=	M4qyeHNCVkeHUh?=
SF126	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LuR2lEPTB;MD6xO\|A3OyEQvF2=	M3;lOnNCVkeHUh?=
CTB-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojaTWM2OD1yLkG3N\|E3KM7:TR?=	MnjZV2FPT0WU
CA46	NGfv[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{Hu[WlEPTB;MD6xO\|Q5QSEQvF2=	NFrDOYZUSU6JRWK=
NCI-H520	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHyTWM2OD1yLkG3O\|MzKM7:TR?=	MmfRV2FPT0WU
CAL-85-1	NGO3T3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfEcYlFUUN3ME2wMlE4QTJ5IN88US=>	NYm0boduW0GQR1XS
NCI-H2342	MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFGxcJNKSzVyPUCuNVg2PzdizszN	NXjDWGM{W0GQR1XS
697	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTBwMUi4O\|Eh\|ryP	NUPMTGZLW0GQR1XS
NY	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfVS3NWUUN3ME2wMlE6Ojh5IN88US=>	NHnVeJZUSU6JRWK=
T98G	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTxRmdSUUN3ME2wMlE6OzF6IN88US=>	M3\UZ3NCVkeHUh?=
NCI-H1703	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIntZmZKSzVyPUCuNVk3OTVizszN	Mne0V2FPT0WU
NCI-H2087	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlryTWM2OD1yLkKwOFM6KM7:TR?=	MmW2V2FPT0WU
PF-382	MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwMkC4O\|Mh\|ryP	MUTTRW5ITVJ?
HCT-116	M2X0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mon4TWM2OD1yLkKxNFY6KM7:TR?=	NX3Nbnp5W0GQR1XS
CAKI-1	MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoC1TWM2OD1yLkKxOlY3KM7:TR?=	M{GxV3NCVkeHUh?=
CCF-STTG1	M3XRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\LTWM2OD1yLkKyOFc2KM7:TR?=	MkXYV2FPT0WU
D-392MG	NVfN[JVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF:yUnJKSzVyPUCuNlMyPzdizszN	NVXFeFRPW0GQR1XS
RT-112	NWK1O4NET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkD5TWM2OD1yLkKzO\|k2KM7:TR?=	NW\pe3NEW0GQR1XS
MES-SA	M{DreWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTLOGRKSzVyPUCuNlQyQDdizszN	NX3PWnd6W0GQR1XS
LC-2-ad	M2ruNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzvW\|hFUUN3ME2wMlI1OjZ3IN88US=>	NELm[25USU6JRWK=
NOS-1	MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDNVVZyUUN3ME2wMlI1OzZ5IN88US=>	M{DPc3NCVkeHUh?=
NALM-6	M3P3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEno[ItKSzVyPUCuNlU2PDNizszN	MXLTRW5ITVJ?
TE-15	NHPvd4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37hXmlEPTB;MD6yOlA6OSEQvF2=	MXfTRW5ITVJ?
786-0	NGHBSHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\HW5lDUUN3ME2wMlI3OjJ6IN88US=>	M{i0b3NCVkeHUh?=
IST-MES1	M1:wRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3NTWM2OD1yLkK2PFI6KM7:TR?=	M1PaRnNCVkeHUh?=
KYSE-180	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTBwMk[4PVEh\|ryP	NHrXfGdUSU6JRWK=
YT	M1HzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;scmlEPTB;MD6yOlk4PCEQvF2=	M3;RVnNCVkeHUh?=
A427	MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TwUWlEPTB;MD6yO\|I3PCEQvF2=	NXztR4pOW0GQR1XS
KYSE-450	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\sTWM2OD1yLkK3N\|I6KM7:TR?=	MUfTRW5ITVJ?
HuH-7	MojQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPvTWM2OD1yLkK3O\|Y{KM7:TR?=	MYLTRW5ITVJ?
CAS-1	NX7uWlBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnflTWM2OD1yLkK4N\|A{KM7:TR?=	MnrmV2FPT0WU
KURAMOCHI	NVTzVnRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnVTWM2OD1yLkK4OFE6KM7:TR?=	MkX5V2FPT0WU
ACHN	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLMTWM2OD1yLkK5N\|I{KM7:TR?=	M{HVenNCVkeHUh?=
HGC-27	Mor1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTJTWM2OD1yLkK5N\|U{KM7:TR?=	NIDaeJVUSU6JRWK=
A172	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEKxd2ZKSzVyPUCuNlk2PzdizszN	MmD3V2FPT0WU
SNU-449	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPOcmZXUUN3ME2wMlI6QTZ2IN88US=>	MoDXV2FPT0WU
SW982	NH:2ZohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnwOlVCUUN3ME2wMlI6QTd6IN88US=>	MVvTRW5ITVJ?
EFO-21	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nYSWlEPTB;MD6zNFQyOSEQvF2=	NX\6b3Z4W0GQR1XS
NCI-H2030	NHm0fYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTBwM{GxOlQh\|ryP	NUPPfnZVW0GQR1XS
HT-144	NVznO5lnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXizUnJXUUN3ME2wMlMyOjhizszN	M3PuSnNCVkeHUh?=
MFE-280	MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXteXZ4UUN3ME2wMlMyPDV\|IN88US=>	NVz1[2x6W0GQR1XS
SK-LU-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzhTWM2OD1yLkOxOFY3KM7:TR?=	MVPTRW5ITVJ?
NCI-H2052	NEHuVYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoD2TWM2OD1yLkOxOFg1KM7:TR?=	NHi1SGhUSU6JRWK=
SK-HEP-1	NIfO[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHwbVVIUUN3ME2wMlM{OzZ6IN88US=>	NXvhZWpOW0GQR1XS
QIMR-WIL	NITpdJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjHPYxKSzVyPUCuN\|M1OjRizszN	NXfifYt2W0GQR1XS
A2780	NVGwcINHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;OTWM2OD1yLkO0N\|A1KM7:TR?=	NGe4bllUSU6JRWK=
ACN	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzTTWM2OD1yLkO0PFc{KM7:TR?=	MVjTRW5ITVJ?
BxPC-3	NXizW5J{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTBwM{S5PFkh\|ryP	M37qd3NCVkeHUh?=
BCPAP	MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHITWM2OD1yLkO2NFAyKM7:TR?=	MXXTRW5ITVJ?
HOP-62	NF7sPI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzFVndKSzVyPUCuN\|YyODZizszN	M3Lme3NCVkeHUh?=
SW1710	MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLyUo1GUUN3ME2wMlM3PDV3IN88US=>	NIL6OJJUSU6JRWK=
OPM-2	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTBwM{[0O\|Mh\|ryP	M4\WenNCVkeHUh?=
DBTRG-05MG	MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nS[2lEPTB;MD6zPFA2PCEQvF2=	NVLL[HN4W0GQR1XS
SK-MEL-24	M1L4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTBwM{m3PVEh\|ryP	NYXVWIFuW0GQR1XS
8305C	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfyTWM2OD1yLkO5O\|k{KM7:TR?=	MnXSV2FPT0WU
OVCAR-4	M{f5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTBwNEG1PFYh\|ryP	NX;vXIk4W0GQR1XS
HLE	NVHGR2xiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTBwNEG4OkDPxE1?	NYjqXJdlW0GQR1XS
NCI-H747	MnLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwNEKxN\|ch\|ryP	MkezV2FPT0WU
SW780	MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwNEKzOFYh\|ryP	NWjlNYpqW0GQR1XS
KYSE-150	Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHTXIQxUUN3ME2wMlQzPDF3IN88US=>	MYLTRW5ITVJ?
H4	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfIbINKSzVyPUCuOFI1PTFizszN	MWnTRW5ITVJ?
SW1088	NWj0OHJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3iyW2lEPTB;MD60OFM6KM7:TR?=	NGHxfmxUSU6JRWK=
SF268	MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;O[\|U{UUN3ME2wMlQ1QDZizszN	MULTRW5ITVJ?
RT4	NUT1PFd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzuWItVUUN3ME2wMlQ2OTFzIN88US=>	M4LWUHNCVkeHUh?=
NCI-H522	MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XpfGlEPTB;MD60OVI4KM7:TR?=	NFTwS45USU6JRWK=
LCLC-97TM1	M3jse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7WdolKUUN3ME2wMlQ3OTl3IN88US=>	Mk[yV2FPT0WU
CAL-39	MlTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTBwNE[1NVkh\|ryP	MoH6V2FPT0WU
CAL-120	M4nYV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTBwNEe2OFMh\|ryP	Mk\IV2FPT0WU
ESS-1	NWXaeVFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jxSWlEPTB;MD60O\|gzOSEQvF2=	MY\TRW5ITVJ?
KARPAS-45	NEH5cmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTBwNEi5N\|Mh\|ryP	MXzTRW5ITVJ?
DU-4475	MmnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTBwNEm1NVEh\|ryP	NGnLUZNUSU6JRWK=
VMRC-RCZ	NXzWVlY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHSTWM2OD1yLkS5PVA1KM7:TR?=	MXLTRW5ITVJ?
HOS	MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwNUCzOlUh\|ryP	MVnTRW5ITVJ?
MOLT-16	NH7R[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwNUG4NFgh\|ryP	M2DucXNCVkeHUh?=
RPMI-6666	NYXqfIRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nPcmlEPTB;MD61NlE{PSEQvF2=	MX3TRW5ITVJ?
K052	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzYTWM2OD1yLkWyNVQh\|ryP	NX7SfZl1W0GQR1XS
EHEB	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPKe2FUUUN3ME2wMlUzOTh{IN88US=>	NWjzVlZOW0GQR1XS
MFH-ino	M1PSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\C[Gx2UUN3ME2wMlUzOzVzIN88US=>	MXzTRW5ITVJ?
A4-Fuk	Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIG0WGJKSzVyPUCuOVI2OjhizszN	NE\0ZopUSU6JRWK=
SW1417	NF;1SpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTBwNUK3PFEh\|ryP	MXnTRW5ITVJ?
DoTc2-4510	NUDGZ3JlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTlfWhKSzVyPUCuOVQ6PThizszN	MV3TRW5ITVJ?
TE-12	M{LDPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTBwNUW3N\|Uh\|ryP	NIP2PZBUSU6JRWK=
8-MG-BA	NXHmemFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHftSIpKSzVyPUCuOVYxPTZizszN	MnvPV2FPT0WU
ECC12	MnS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjiW5ZJUUN3ME2wMlU3PTV6IN88US=>	MYrTRW5ITVJ?
CHL-1	NGHQd5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwNUe0OlMh\|ryP	NIrVOlRUSU6JRWK=
LCLC-103H	Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XVTmlEPTB;MD61PFM1PCEQvF2=	MnjVV2FPT0WU
OS-RC-2	MmTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH33WGZKSzVyPUCuOVg{PzlizszN	NV;GUodZW0GQR1XS
RO82-W-1	M{LaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTHU\|BDUUN3ME2wMlU6PjF3IN88US=>	MmD5V2FPT0WU
A3-KAW	MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvLbVIxUUN3ME2wMlYyPDZ5IN88US=>	MWXTRW5ITVJ?
NCCIT	NVSxZopFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\5SJNKSzVyPUCuOlE4OTVizszN	NFzBbnJUSU6JRWK=
IST-SL2	M{jOUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULiXJNbUUN3ME2wMlYzPTJ{IN88US=>	MYXTRW5ITVJ?
GI-ME-N	MofHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDjVoJKSzVyPUCuOlMxPjlizszN	MY\TRW5ITVJ?
ES6	MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTBwNkOyPVUh\|ryP	NYLtWIJVW0GQR1XS
BL-41	NGrxenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHaRlZKSzVyPUCuOlM{PTJizszN	NEm4V3pUSU6JRWK=
Ca-Ski	M4DjW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLvR2lKSzVyPUCuOlQ5OSEQvF2=	MWjTRW5ITVJ?
HOP-92	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGqzR5dKSzVyPUCuOlU3PzJizszN	NFL1VJVUSU6JRWK=
SK-LMS-1	NUCxbm0yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTBwNk[0O{DPxE1?	MVzTRW5ITVJ?
EW-13	M1G2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTBwNk[3O\|kh\|ryP	NVjJR5Z5W0GQR1XS
647-V	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoflTWM2OD1yLk[4NVQ5KM7:TR?=	M4G1ZXNCVkeHUh?=
JiyoyeP-2003	NWjCOoh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFmzTmRKSzVyPUCuOlk4OzhizszN	NV\5TItxW0GQR1XS
WSU-NHL	MoXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLyTWM2OD1yLkewPFg4KM7:TR?=	NEGy[JZUSU6JRWK=
U-698-M	M1LMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwN{GwOlMh\|ryP	MkPFV2FPT0WU
HC-1	NXzx[\|J3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnXWFVNUUN3ME2wMlczPDB3IN88US=>	M3XTS3NCVkeHUh?=
8505C	NVvNSFJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVu3U4hlUUN3ME2wMlczPzRzIN88US=>	MV;TRW5ITVJ?
HUTU-80	MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MortTWM2OD1yLkezN\|Q6KM7:TR?=	M4fuRnNCVkeHUh?=
LB1047-RCC	NXPHWI9GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULkZpJHUUN3ME2wMlc{PTN6IN88US=>	NEDSTWNUSU6JRWK=
GAMG	NW\B[\|hwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTUT\|lKSzVyPUCuO\|M3PTNizszN	NVHkVI1LW0GQR1XS
CAL-12T	NFSyUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvoTWM2OD1yLkezPFc4KM7:TR?=	M1n0SnNCVkeHUh?=
NCI-SNU-1	NGHDVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTBwN{eyO\|gh\|ryP	NFLzOppUSU6JRWK=
HTC-C3	M3jxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWL3SmNFUUN3ME2wMlc4PDVzIN88US=>	MWnTRW5ITVJ?
HPAF-II	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\GU4hKSzVyPUCuO\|c2ODFizszN	NFjoTpJUSU6JRWK=
KGN	M1nId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnYc3pUUUN3ME2wMlc5ODhzIN88US=>	MXvTRW5ITVJ?
EFO-27	NYTuXVI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nZPGlEPTB;MD63PFc{OyEQvF2=	MlvFV2FPT0WU
MEL-HO	NWjZTWp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XzU2lEPTB;MD63PVQ1QSEQvF2=	Mm[5V2FPT0WU
KYSE-270	NWfmc\|Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjUTWM2OD1yLkiwOVI6KM7:TR?=	NEHxXlhUSU6JRWK=
NCI-H1755	NILIdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwOEC3NVQh\|ryP	NX7lSlNlW0GQR1XS
MFM-223	NIXjW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2H3eGlEPTB;MD64NVQxPyEQvF2=	NIPvS2RUSU6JRWK=
G-361	NF\VcHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TCO2lEPTB;MD64NVg6PyEQvF2=	NVHIVnFGW0GQR1XS
ETK-1	M2XSbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXtTWM2OD1yLkiyOFQyKM7:TR?=	M2\MWnNCVkeHUh?=
LU-99A	NHrrdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEeyXWJKSzVyPUCuPFQ4ODFizszN	NEXWcnJUSU6JRWK=
IST-MEL1	NXe0fZNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\qfWlEPTB;MD64OVc{OiEQvF2=	NX63bFByW0GQR1XS
L-540	NYXaT3htT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nBNGlEPTB;MD64OVgxOSEQvF2=	NF\uUI1USU6JRWK=
U-2-OS	MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwOEW4OFYh\|ryP	M2rDU3NCVkeHUh?=
HT-1376	M2jNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fRfGlEPTB;MD64OlA2OSEQvF2=	NXT4TItnW0GQR1XS
COLO-680N	Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XNNGlEPTB;MD64O\|k{OyEQvF2=	NGTOXIdUSU6JRWK=
NCI-H1581	M2GyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHn5eHdKSzVyPUCuPFkzQTdizszN	NF[wenBUSU6JRWK=
HuCCT1	NWHDUZZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwOEm1OFgh\|ryP	Ml24V2FPT0WU
BB30-HNC	M1;6OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofnTWM2OD1yLkmyOFY6KM7:TR?=	NIXhbpZUSU6JRWK=
NCI-H2347	MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\yTWM2OD1yLkmzNlkzKM7:TR?=	M3fkS3NCVkeHUh?=
G-401	NFHB[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzK[lJDUUN3ME2wMlk{Pjl3IN88US=>	M1HiWXNCVkeHUh?=
NCI-H358	M2f6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwOUWwNVQh\|ryP	NEj1epRUSU6JRWK=
HCC1395	Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\vUWlEPTB;MD65OVQ3OSEQvF2=	NVr6PYlQW0GQR1XS
J82	M{i0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojwTWM2OD1yLkm1OVQ{KM7:TR?=	NUe1WY5KW0GQR1XS
KE-37	M1TLcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\ZR5FKSzVyPUCuPVY{QDdizszN	NYPuN5pHW0GQR1XS
NOMO-1	NITHOJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwOU[1OlQh\|ryP	Mmr2V2FPT0WU
ML-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwOUm3OUDPxE1?	NEPQN4FUSU6JRWK=
SW872	MlvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HRWmlEPTB;MD65PVc4PSEQvF2=	MlPlV2FPT0WU
KYSE-520	M4rlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjScHdKSzVyPUGuNFA1QTRizszN	NUfjd3hOW0GQR1XS
HL-60	NEL4TFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULycnRjUUN3ME2xMlAxQTdizszN	NXLSfm9UW0GQR1XS
HDLM-2	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHzW5RKSzVyPUGuNFEzPTJizszN	MmHuV2FPT0WU
MIA-PaCa-2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7veZdKSzVyPUGuNFE{PzVizszN	NFz4UnlUSU6JRWK=
TCCSUP	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPVR4xNUUN3ME2xMlAyPzN{IN88US=>	MlHlV2FPT0WU
SH-4	NEDVVGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHpTWM2OD1zLkCyNlQ1KM7:TR?=	NXTEV4FwW0GQR1XS
MG-63	M1K0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHe0S3ZKSzVyPUGuNFI3OTZizszN	MmDMV2FPT0WU
NB6	Mn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7wTWM2OD1zLkCzNVA6KM7:TR?=	MlLqV2FPT0WU
CAL-54	NVuzSXptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkO3TWM2OD1zLkCzPVU6KM7:TR?=	NHPNfFRUSU6JRWK=
DU-145	NVuw[GJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLnd5F6UUN3ME2xMlA5ODd\|IN88US=>	NEK0VYRUSU6JRWK=
HCE-4	NV;GdWQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2GwUmlEPTB;MT6wPVI5PiEQvF2=	NVHKSJJ4W0GQR1XS
U-266	MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG[0bmVKSzVyPUGuNFk3OzNizszN	M4HHPXNCVkeHUh?=
HT-1197	NXnPPYZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLOTWM2OD1zLkGxOFM5KM7:TR?=	MVLTRW5ITVJ?
EW-1	M4HZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTFwMUSxNlgh\|ryP	Mo\5V2FPT0WU
MHH-NB-11	NHH1TXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTtR\|lnUUN3ME2xMlE2OzZ6IN88US=>	NUjOS4JvW0GQR1XS
NCI-H2405	MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjLcmtKSzVyPUGuNVYyPiEQvF2=	M1TmenNCVkeHUh?=
COLO-668	NXPCR\|h3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TNW2lEPTB;MT6xOlQ6KM7:TR?=	MYfTRW5ITVJ?
IMR-5	MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTtUINDUUN3ME2xMlE3QTN4IN88US=>	Moe1V2FPT0WU
ARH-77	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTFwMkK5NlQh\|ryP	NHTJcZBUSU6JRWK=
BHT-101	NVjP[FRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWe4NIJ{UUN3ME2xMlI{PDlizszN	NX[5SFd5W0GQR1XS
SCC-25	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzhO2piUUN3ME2xMlI{PTN4IN88US=>	M1rLV3NCVkeHUh?=
NTERA-S-cl-D1	M4\IU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXu0O2I{UUN3ME2xMlI1OzR4IN88US=>	MWTTRW5ITVJ?
MKN28	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jCXGlEPTB;MT6yOVY{PiEQvF2=	NFmyfJFUSU6JRWK=
KS-1	M3nh[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzuTWM2OD1zLkK4NlY6KM7:TR?=	M2[3WnNCVkeHUh?=
NCI-H1734	NFLGVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITUOFJKSzVyPUGuNlg6OTNizszN	Mle4V2FPT0WU
ES7	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLFZpBKSzVyPUGuNlk2PDJizszN	MlXQV2FPT0WU
NCI-H838	MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoP4TWM2OD1zLkOwOlE2KM7:TR?=	MYXTRW5ITVJ?
HEC-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPmTWM2OD1zLkOzO\|U2KM7:TR?=	NITqVpRUSU6JRWK=
ME-180	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGSzXmhKSzVyPUGuN\|c6QTNizszN	MXHTRW5ITVJ?
MMAC-SF	M4jocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHkTWM2OD1zLkO5OVk2KM7:TR?=	MWHTRW5ITVJ?
IA-LM	NXzhcZNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnSyTWM2OD1zLkSwPVE1KM7:TR?=	M2PES3NCVkeHUh?=
MN-60	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvPXWNKSzVyPUGuOFMyOTRizszN	MUTTRW5ITVJ?
SIMA	NXr6PFNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rHRmlEPTB;MT60PFY5PyEQvF2=	NIPGfVRUSU6JRWK=
NCI-H1770	NXXMNZhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnUTWM2OD1zLkWyNFU1KM7:TR?=	NVXGVoEzW0GQR1XS
ONS-76	NV;nblZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTFwNUKzNVEh\|ryP	MV3TRW5ITVJ?
LB771-HNC	MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTFwNUO5NFYh\|ryP	MVnTRW5ITVJ?
SW48	M1rSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTFwNUSyOFMh\|ryP	NI\EeHlUSU6JRWK=
KYSE-140	NVr0SWp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1K2cGlEPTB;MT61OVc1OSEQvF2=	M17lUXNCVkeHUh?=
SW626	NWTuOFJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zLdGlEPTB;MT61PFE3KM7:TR?=	MX;TRW5ITVJ?
MC-CAR	NGD4UmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvNTWM2OD1zLkW4OlY{KM7:TR?=	M2G2WHNCVkeHUh?=
D-336MG	NVGwR5NYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\3N5pzUUN3ME2xMlYzQTRizszN	NWDCe3RwW0GQR1XS
SK-MEL-3	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTFwNkO5NFIh\|ryP	NInyR3FUSU6JRWK=
MHH-PREB-1	M4L1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfPR5hVUUN3ME2xMlY1PDd\|IN88US=>	NGnPe4hUSU6JRWK=
Calu-1	NU[zcnRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTkTWM2OD1zLk[1N\|g3KM7:TR?=	MVrTRW5ITVJ?
HCC1806	M4\l[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TLVmlEPTB;MT62OlYyOSEQvF2=	NXL4XXoxW0GQR1XS
A101D	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorZTWM2OD1zLk[2O\|gyKM7:TR?=	M2LkdnNCVkeHUh?=
A704	NILwcmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\jdWlEPTB;MT62PFMyOSEQvF2=	MmjRV2FPT0WU
LB831-BLC	NGXicVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnqwTWM2OD1zLk[5PFU1KM7:TR?=	Mn7mV2FPT0WU
RL95-2	M1f3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVT0OINzUUN3ME2xMlcyPDZ\|IN88US=>	Ml;sV2FPT0WU
RPMI-2650	NUSze2xKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLrTWM2OD1zLkeyO\|E6KM7:TR?=	NEH6VIRUSU6JRWK=
NH-12	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3jT2dKSzVyPUGuO\|M1OjdizszN	NHvENYhUSU6JRWK=
AGS	M2D0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rqSmlEPTB;MT63OlM2QCEQvF2=	NHPnN\|JUSU6JRWK=
NEC8	NXi1ZYhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3r2WmlEPTB;MT63PFk6PSEQvF2=	MWTTRW5ITVJ?
NCI-H2009	MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTCNGZJUUN3ME2xMlc6PzJzIN88US=>	MnHvV2FPT0WU
A498	M3zpc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHB[o9IUUN3ME2xMlgyOjh{IN88US=>	NWrMW3ZmW0GQR1XS
NCI-H810	NHLGRYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULQXYU3UUN3ME2xMlgyPjB4IN88US=>	NUHqNFlEW0GQR1XS
SK-NEP-1	NVi2Vm13T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoT0TWM2OD1zLkizO\|Y4KM7:TR?=	MULTRW5ITVJ?
D-542MG	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFmzZ2FKSzVyPUGuPFU5PTFizszN	M3zIRXNCVkeHUh?=
KNS-42	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TkXWlEPTB;MT64OlI3PiEQvF2=	MYXTRW5ITVJ?
NCI-H2452	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XpZ2lEPTB;MT64PVA4PCEQvF2=	MWjTRW5ITVJ?
SK-MEL-2	M175emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nBR2lEPTB;MT65NFI4OSEQvF2=	NV;rZodUW0GQR1XS
OVCAR-5	NGfvSohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXRXms1UUN3ME2xMlkxPjd3IN88US=>	NUj0XYQ5W0GQR1XS
SNG-M	NWPLenVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TFVGlEPTB;MT65OVg2QCEQvF2=	M37xN3NCVkeHUh?=
A673	M3rkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;CPGlEPTB;MT65O\|UyPiEQvF2=	NVq0U5g{W0GQR1XS
L-428	NUS1e\|ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkS2TWM2OD1zLkm5NVc6KM7:TR?=	MVPTRW5ITVJ?
KM-H2	NUL3S25HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTJwMEGwPUDPxE1?	NWDtO\|JRW0GQR1XS
MC-IXC	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTJwMEKyO\|Mh\|ryP	MXrTRW5ITVJ?
COLO-678	M2fBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHRNpZKSzVyPUKuNFQzODdizszN	NVPOcHhiW0GQR1XS
MEL-JUSO	M4\Jc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2T4NWlEPTB;Mj6wO\|g2OSEQvF2=	MWnTRW5ITVJ?
HCC38	M4nkOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fndGlEPTB;Mj6wPFQ{OyEQvF2=	MnzMV2FPT0WU
UACC-62	NXLFNmZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnUTWM2OD1{LkC4PFU2KM7:TR?=	MlrWV2FPT0WU
OAW-42	MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\WTWM2OD1{LkC5O\|EyKM7:TR?=	M1f5fnNCVkeHUh?=
LB996-RCC	MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\wOVRHUUN3ME2yMlE{QDF5IN88US=>	MUjTRW5ITVJ?
COR-L105	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fRO2lEPTB;Mj6xOlM4OyEQvF2=	NYX2ZllOW0GQR1XS
RCC10RGB	M4LidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTJwMUi1O\|Yh\|ryP	MVXTRW5ITVJ?
A431	NIf2WWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELCdGhKSzVyPUKuNVkxOTlizszN	MVPTRW5ITVJ?
NCI-H292	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3n3PGlEPTB;Mj6yN\|k2OSEQvF2=	MU\TRW5ITVJ?
SK-UT-1	M1LabGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPwTWM2OD1{LkOzNVg1KM7:TR?=	M2izWnNCVkeHUh?=
PANC-08-13	M{LYdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTJwM{OyN\|Uh\|ryP	MVjTRW5ITVJ?
ST486	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYm0U4xOUUN3ME2yMlQyODR6IN88US=>	NUXafVh3W0GQR1XS
SJSA-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\BSY8{UUN3ME2yMlQyOjdzIN88US=>	M3ztNHNCVkeHUh?=
RKO	MmD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17EV2lEPTB;Mj60NlAzQSEQvF2=	NYHFSYJuW0GQR1XS
NCI-H1793	M{D0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX23T4ZTUUN3ME2yMlQ1ODJ7IN88US=>	MX7TRW5ITVJ?
639-V	MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;ISndLUUN3ME2yMlQ2Ozh{IN88US=>	NUHSbIZrW0GQR1XS
ES3	NIq2fIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnMenZ2UUN3ME2yMlQ6PzN5IN88US=>	NXTw[20yW0GQR1XS
NCI-H1792	MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnlNYVPUUN3ME2yMlU3QDJ4IN88US=>	NU\FfWJ5W0GQR1XS
NCI-H1651	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zxV2lEPTB;Mj61PFIyKM7:TR?=	MVLTRW5ITVJ?
SN12C	NIPL[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7VTWM2OD1{LkW4OFg4KM7:TR?=	MmnSV2FPT0WU
COLO-679	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPTTWM2OD1{LkW4OlA2KM7:TR?=	MVTTRW5ITVJ?
U-118-MG	NX;RNFd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHieJRKSzVyPUKuOVg5PzJizszN	NUjtVVROW0GQR1XS
Ramos-2G6-4C10	NFfWfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\qXmlEPTB;Mj62OFgxPyEQvF2=	NHLURVBUSU6JRWK=
HCT-15	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTJwNki3PVIh\|ryP	M4TsNXNCVkeHUh?=
MDA-MB-157	MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrYb29CUUN3ME2yMlcxPzR5IN88US=>	MkLlV2FPT0WU
K5	NWHHOHhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFn4fHFKSzVyPUKuO\|E5PDVizszN	NHHTUZpUSU6JRWK=
MKN45	M3vKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;wTWM2OD1{LkezN\|Y3KM7:TR?=	NFzsU5BUSU6JRWK=
DMS-273	M4XiUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzGSlBKSzVyPUKuO\|U3OzJizszN	NFnM[pFUSU6JRWK=
C8166	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTkTWM2OD1{Lke4OVE{KM7:TR?=	NYPUOmpJW0GQR1XS
Calu-3	NIHxZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PWdmlEPTB;Mj63PFk3QSEQvF2=	MUfTRW5ITVJ?
SNB75	NEfzb2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTJwOEi1N\|Uh\|ryP	NHrXToVUSU6JRWK=
BFTC-905	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7LUm5KSzVyPUKuPVAyQTFizszN	M1GyO3NCVkeHUh?=
C-4-II	NUKwNWF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWW2O\|I1UUN3ME2yMlkyOzV\|IN88US=>	M2HKcnNCVkeHUh?=
MS-1	M2jNdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTJwOU[3Olkh\|ryP	M4iyVXNCVkeHUh?=
A375	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1i2TWlEPTB;Mz6wPFE5PCEQvF2=	Mlz3V2FPT0WU
KYSE-70	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTNwMEi4PFIh\|ryP	M4\yXnNCVkeHUh?=
KYSE-510	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPHZ4d6UUN3ME2zMlExQTl3IN88US=>	MYXTRW5ITVJ?
LN-405	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnz[o9kUUN3ME2zMlE{PTF6IN88US=>	NFHWZpJUSU6JRWK=
BOKU	M4fM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTNwMUSyOVYh\|ryP	MmDzV2FPT0WU
TE-10	Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjIRWpKSzVyPUOuNVc{PjJizszN	NG[1SIFUSU6JRWK=
MKN1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPBc3FKSzVyPUOuNVg1QDNizszN	NYf4W2VLW0GQR1XS
M059J	NVKwT3c5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2m1bmlEPTB;Mz6yNFE4OyEQvF2=	NHvSZ4pUSU6JRWK=
GOTO	M1jrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTYZYhSUUN3ME2zMlIzODN7IN88US=>	MkLTV2FPT0WU
DK-MG	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHr2TJNKSzVyPUOuNlU6PzZizszN	MVHTRW5ITVJ?
NCI-H727	NVvIT2NlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDPcXIxUUN3ME2zMlI3PThizszN	NF3RSXBUSU6JRWK=
NB12	MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLLTWM2OD1\|LkOzNlI1KM7:TR?=	MYDTRW5ITVJ?
DOK	NImzSnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTNwM{[xPFYh\|ryP	NFrjfphUSU6JRWK=
KYSE-410	M2n2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVf0XGIzUUN3ME2zMlM3Ojh5IN88US=>	M3f5b3NCVkeHUh?=
AM-38	NYf0e5Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfoT2Q3UUN3ME2zMlM5ODVzIN88US=>	NVjycHNIW0GQR1XS
GR-ST	NHixbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHUd2lKSzVyPUOuOFU4OzJizszN	MVfTRW5ITVJ?
D-247MG	M1zGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjCV4lKSzVyPUOuOFgzPjNizszN	M3fMZnNCVkeHUh?=
TE-8	M4\ITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWSzbXlkUUN3ME2zMlQ6OzN\|IN88US=>	NUT2RpBIW0GQR1XS
LS-411N	NUPBWXVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jLb2lEPTB;Mz60PVY6OiEQvF2=	MonjV2FPT0WU
SK-MES-1	Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnMemtKSzVyPUOuOVY1OzNizszN	NFvQT5NUSU6JRWK=
SF295	NVvGVGZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3NTWM2OD1\|Lk[xOVUzKM7:TR?=	NVf3PWhuW0GQR1XS
SK-MEL-30	NG\vZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITSV4hKSzVyPUOuOlU6OjFizszN	MYHTRW5ITVJ?
LB2241-RCC	M1nlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33remlEPTB;Mz62OlI3KM7:TR?=	MU\TRW5ITVJ?
PC-14	M1n0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVft[\|RyUUN3ME2zMlY3PDN5IN88US=>	NEHycopUSU6JRWK=
EW-7	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTNwNke2PVMh\|ryP	M4riSHNCVkeHUh?=
NMC-G1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\aPYhKSzVyPUOuO\|E5OzdizszN	M3i0dHNCVkeHUh?=
TE-441-T	MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfJPVRKSzVyPUOuO\|MxOjhizszN	NWfwWHVrW0GQR1XS
NCI-H1618	MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjNXVV[UUN3ME2zMlgyQDd3IN88US=>	M{\abHNCVkeHUh?=
PANC-03-27	M{fXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLpTWM2OD1\|LkixPVE3KM7:TR?=	NHT5eYpUSU6JRWK=
NCI-H2228	NHW2[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nvSGlEPTB;Mz64N\|EzPiEQvF2=	MV\TRW5ITVJ?
CAPAN-1	MmfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHFb\|BKSzVyPUOuPFcxODlizszN	M{HyWHNCVkeHUh?=
KLE	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLXTWM2OD1\|LkmwOlch\|ryP	M4DDcHNCVkeHUh?=
Becker	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\mToFkUUN3ME2zMlkzQDR7IN88US=>	M1LwfHNCVkeHUh?=
SK-PN-DW	NU\ofYo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PwdWlEPTB;ND6wO\|k4PCEQvF2=	NH;4XphUSU6JRWK=
Hs-578-T	NVHwNYpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPYTWM2OD12LkC4N\|A3KM7:TR?=	M3rxcnNCVkeHUh?=
RS4-11	MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTRwMUGyOVUh\|ryP	MWnTRW5ITVJ?
D-502MG	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\OTWM2OD12LkG2PVk4KM7:TR?=	MWDTRW5ITVJ?
GI-1	MnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLiTWM2OD12LkK4Nlk6KM7:TR?=	MX3TRW5ITVJ?
NCI-H209	MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M36xTGlEPTB;ND6zN\|c5KM7:TR?=	NEHiNIpUSU6JRWK=
SK-OV-3	M4XUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIP2ZXVKSzVyPUSuOFgyPDlizszN	MkW4V2FPT0WU
LOUCY	NXLuc3pUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPXW\|BqUUN3ME20MlQ5PDN{IN88US=>	MXvTRW5ITVJ?
NCI-H69	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LnWmlEPTB;ND61NVc6OyEQvF2=	NHK5V5FUSU6JRWK=
SCC-9	NInEc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHkTWM2OD12LkWzNVczKM7:TR?=	MnvBV2FPT0WU
NCI-H526	NELSWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DkZWlEPTB;ND61PVI6OyEQvF2=	MVzTRW5ITVJ?
NCI-H2170	MojOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{foXWlEPTB;ND62Olc4OSEQvF2=	MXnTRW5ITVJ?
SR	NVfGeVF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTRwN{CwOFgh\|ryP	NU\VbYhqW0GQR1XS
CMK	M1XKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfWTWM2OD12LkeyNVAyKM7:TR?=	MV\TRW5ITVJ?
COLO-829	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7BTWM2OD12Lke3NFQ{KM7:TR?=	MXvTRW5ITVJ?
HuO-3N1	NF23eGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTRwOEOyPFEh\|ryP	MkjYV2FPT0WU
5637	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\0O4ZGUUN3ME20MlkxPDh5IN88US=>	M3TyWXNCVkeHUh?=
A253	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrS[IhKSzVyPUSuPVc4ODhizszN	MUnTRW5ITVJ?
NB10	M2O4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYH3OI1mUUN3ME21MlA4PDl5IN88US=>	MV3TRW5ITVJ?
SF539	NHfHR2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVuySmpTUUN3ME21MlA6QTV7IN88US=>	NXzSb29JW0GQR1XS
HAL-01	NXjpTWQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfsTmtiUUN3ME21MlE1PjR3IN88US=>	NEPsR\|dUSU6JRWK=
MHH-ES-1	M4PGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTVwMU[5NlUh\|ryP	M{jGO3NCVkeHUh?=
DEL	NFrOe3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PjS2lEPTB;NT6yO\|U5OiEQvF2=	MYDTRW5ITVJ?
NCI-H1299	NFPkSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILWOmxKSzVyPUWuN\|UxODdizszN	NYTqZ49YW0GQR1XS
ChaGo-K-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjVb29mUUN3ME21MlM2OTB5IN88US=>	MnH4V2FPT0WU
HMV-II	Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXPbWdKSzVyPUWuN\|k1OyEQvF2=	Mn;wV2FPT0WU
NB69	NUDsb45UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInjOVBKSzVyPUWuN\|k3OzFizszN	MVvTRW5ITVJ?
NCI-H1882	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofpTWM2OD13LkSzN\|Y1KM7:TR?=	MX7TRW5ITVJ?
SNU-475	M{DYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\wR3ZKSzVyPUWuOFcyPzFizszN	MorTV2FPT0WU
RXF393	M2D1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzVTWM2OD13LkS4OFk1KM7:TR?=	MkPVV2FPT0WU
CAL-51	Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnhTWM2OD13Lk[yPFU{KM7:TR?=	M3TDWnNCVkeHUh?=
SW1573	Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\MTFY{UUN3ME21MlY{PTN2IN88US=>	NWPmT4pTW0GQR1XS
GCT	NInS[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTVwN{W5Nlkh\|ryP	M1nyfXNCVkeHUh?=
COR-L88	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\6NGlEPTB;NT63Olg1PiEQvF2=	M3;IW3NCVkeHUh?=
MDA-MB-134-VI	Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnubFJKSzVyPUWuPFc2OzZizszN	MXzTRW5ITVJ?
NB5	M{\uNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HsOGlEPTB;NT65NlQ1KM7:TR?=	MX\TRW5ITVJ?
GMS-10	NUn5XGt6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfpWpVKSzVyPUWuPVY5PjFizszN	M2rHdnNCVkeHUh?=
CHP-212	Ml;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIj5[ZNKSzVyPU[uOFgzPjdizszN	MX3TRW5ITVJ?
TE-11	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfrTmE6UUN3ME22MlU2OTh{IN88US=>	NUTTN4ZVW0GQR1XS
SW962	NGnGO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LvZ2lEPTB;Nj62OVc4PCEQvF2=	NXGydYt4W0GQR1XS
MZ2-MEL	NH;DVYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4W5e2lEPTB;Nj64NlAyOSEQvF2=	NWHSfYI4W0GQR1XS
C-33-A	NHjiSWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrVSW1[UUN3ME22MlkyPjh6IN88US=>	MVTTRW5ITVJ?
IGR-1	NGDXfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfVTWM2OD14Lkm3PFI3KM7:TR?=	NHjYbYtUSU6JRWK=
MOLT-4	NH7heYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjCdZJDUUN3ME23MlE2PDB4IN88US=>	M1nWXHNCVkeHUh?=
NCI-H1650	NXXZfG9tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;mb\|FKSzVyPUeuNlcxPDZizszN	M2nhRXNCVkeHUh?=
AsPC-1	MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rxd2lEPTB;Nz6yPFYxPSEQvF2=	MnS2V2FPT0WU
SNU-C2B	NW\IfFh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTdwMkm1O\|Eh\|ryP	NHXQbGJUSU6JRWK=
MKN7	NF3SVm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPETWM2OD15LkO3NlM2KM7:TR?=	MlvnV2FPT0WU
SW620	NYjJWllwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjudldKSzVyPUeuN\|gzODVizszN	MnnxV2FPT0WU
SK-MEL-28	M{nxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4W1S2lEPTB;Nz60NFc6QCEQvF2=	M2Lr[nNCVkeHUh?=
TE-6	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTJN25pUUN3ME23MlQ1QTB6IN88US=>	NGj5ZXlUSU6JRWK=
D-263MG	MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHe3fJFKSzVyPUeuOFU4PjJizszN	NW\nPIdWW0GQR1XS
NCI-H1355	MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjTd5BKSzVyPUeuO\|cxOjlizszN	NWPyRWQ2W0GQR1XS
DSH1	NYP5Zo1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\Ec29KSzVyPUeuO\|k4PjJizszN	M2jKeXNCVkeHUh?=
NCI-H460	NEXud49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIi2U2lKSzVyPUiuNFA3QTRizszN	MV3TRW5ITVJ?
NCI-H1563	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrRNGpKSzVyPUiuNFc2ODhizszN	MYjTRW5ITVJ?
SW948	NELH[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojRTWM2OD16LkGwO\|Q1KM7:TR?=	NV\6fG5DW0GQR1XS
LK-2	NIP2NXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjoSG1KSzVyPUiuNVI5OzNizszN	MWnTRW5ITVJ?
HT-1080	NUX2eIdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnHV\|NDUUN3ME24MlE{OTd3IN88US=>	NX63e4JxW0GQR1XS
NCI-H441	NXvOTGhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVO2[WQ4UUN3ME24MlE6OyEQvF2=	NGDVeJFUSU6JRWK=
HSC-4	M1PQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPOeZNnUUN3ME24MlI5PzJizszN	M4TYUnNCVkeHUh?=
LXF-289	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\RTWM2OD16LkO1PVQ{KM7:TR?=	NYHMdW8xW0GQR1XS
MRK-nu-1	M17RTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFW3OVZKSzVyPUiuN\|Y{ODRizszN	MVvTRW5ITVJ?
no-11	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1frVmlEPTB;OD60O\|E{OyEQvF2=	MknWV2FPT0WU
SNU-387	NUDKfolVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fMcmlEPTB;OD62N\|I1PiEQvF2=	NHfySoVUSU6JRWK=
Detroit562	M3nTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDuTWM2OD16Lke1OFU2KM7:TR?=	Mm\PV2FPT0WU
SW954	MnH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfHTWM2OD16Lke2PFMzKM7:TR?=	NELKU3FUSU6JRWK=
P12-ICHIKAWA	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRThwN{i5OEDPxE1?	M135NXNCVkeHUh?=
TE-9	M2\VZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGj5XmxKSzVyPUiuPFExPjJizszN	MULTRW5ITVJ?
NB13	NHLW[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrtTWM2OD16LkizO\|k3KM7:TR?=	MUDTRW5ITVJ?
BPH-1	M{HDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13JNmlEPTB;OD64OVA5OSEQvF2=	NU\y[XJRW0GQR1XS
KMOE-2	NFrjSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\hXJNKSzVyPUiuPFc5QTJizszN	MojTV2FPT0WU
RPMI-8402	NX\sVFBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkO5TWM2OD16Lki5PVI3KM7:TR?=	MmDLV2FPT0WU
OVCAR-3	NEXC[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzvRY9KSzVyPUiuPVc4OzJizszN	MorLV2FPT0WU
NCI-H2196	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjM[HJTUUN3ME24Mlk5PjB4IN88US=>	NInyUJhUSU6JRWK=
MZ7-mel	NV3ZUVJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHs[oFKSzVyPUmuNFM1PiEQvF2=	NYWzOmxJW0GQR1XS
GP5d	NF;5SoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfLTWM2OD17LkC2N\|E{KM7:TR?=	MUTTRW5ITVJ?
NCI-N87	MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmP5TWM2OD17LkS0O\|MyKM7:TR?=	NYLjWHFIW0GQR1XS
EW-16	MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTlwNES4OFgh\|ryP	M135enNCVkeHUh?=
Calu-6	NF[xdJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTlwNEm3NFMh\|ryP	MVfTRW5ITVJ?
LC4-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTlwNkK1O{DPxE1?	M1fZS3NCVkeHUh?=
CCRF-CEM	M3zqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXvTWM2OD17Lk[4O\|Y3KM7:TR?=	NUL2foQ6W0GQR1XS
BC-1	M2j6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjndINKSzVyPUmuO\|g6QSEQvF2=	NUPXfJBXW0GQR1XS
NCI-SNU-16	NHnzdHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTlwN{m0PVUh\|ryP	M2jGOXNCVkeHUh?=
NCI-H28	MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTlwOES5N\|Mh\|ryP	NHu5b\|FUSU6JRWK=
SBC-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXQOJhqUUN3ME2xNE4xPzJizszN	MmrYV2FPT0WU
TUR	M37ES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHVUVlWUUN3ME2xNE4yPjV5IN88US=>	M3r1fHNCVkeHUh?=
MDA-MB-231	M4nBN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rON2lEPTB;MUCuNlEyPCEQvF2=	MmCyV2FPT0WU
C3A	NX6w[HVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTFyLkOxO\|kh\|ryP	NXr4NpV7W0GQR1XS
SW1990	NHHoTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorITWM2OD1zMD6zNlgh\|ryP	NVPVSm1SW0GQR1XS
NCI-H1993	NHTsOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XUcWlEPTB;MUCuOVY6OyEQvF2=	NWrDXmtDW0GQR1XS
SK-CO-1	NG\jfG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{j6eGlEPTB;MUCuO\|c4KM7:TR?=	NXSxbmNzW0GQR1XS
OAW-28	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrITWM2OD1zMD65PFg5KM7:TR?=	Mn3ZV2FPT0WU
HN	NFzKTnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml70TWM2OD1zMT6xNVMyKM7:TR?=	NHPZOlJUSU6JRWK=
NCI-H1304	M4nBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vGVGlEPTB;MUGuNVU4PiEQvF2=	NECzWYtUSU6JRWK=
Daoy	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVj2NnJ7UUN3ME2xNU41OzN4IN88US=>	MmTGV2FPT0WU
VA-ES-BJ	Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTFzLkexPVUh\|ryP	NVHH[nFIW0GQR1XS
MCF7	M4O5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLhTWM2OD1zMT64NVI3KM7:TR?=	NETpcXJUSU6JRWK=
VM-CUB-1	NUD1e3h7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYj5bW13UUN3ME2xNU46ODlzIN88US=>	NFKyPZJUSU6JRWK=
IPC-298	M1\oUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\ITWM2OD1zMT65N\|g{KM7:TR?=	MUjTRW5ITVJ?
NCI-H2126	Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTF{LkCyNVgh\|ryP	Ml;RV2FPT0WU
OVCAR-8	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrQb2dKSzVyPUGyMlEyPDFizszN	M2fqV3NCVkeHUh?=
SJRH30	MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\WTWM2OD1zMj6yNlk6KM7:TR?=	MWXTRW5ITVJ?
DMS-53	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\mOYNKSzVyPUGyMlI3PDlizszN	M4S2bnNCVkeHUh?=
NCI-H322M	NUWwSVd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTF{LkOzOVch\|ryP	Mn7zV2FPT0WU
RVH-421	NY\TWY1nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnS0TWM2OD1zMj60PVA1KM7:TR?=	NHniSmhUSU6JRWK=
Raji	M2HB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTxTWM2OD1zMj62NVQh\|ryP	NXjTZZlMW0GQR1XS
MDA-MB-415	MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;rZXdTUUN3ME2xNk43PDR2IN88US=>	MXvTRW5ITVJ?
EFE-184	NH\EfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFW5c4lKSzVyPUGyMlcyODZizszN	NXLuNWxRW0GQR1XS
BFTC-909	NGX3e5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTF{LkmyOFch\|ryP	NYK5b3gyW0GQR1XS
BHY	MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LPcGlEPTB;MUOuN\|M6KM7:TR?=	MXTTRW5ITVJ?
YKG-1	M2i1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYficpp3UUN3ME2xN{4{PzR7IN88US=>	MmfHV2FPT0WU
EW-3	M4[3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTBZ5JKSzVyPUGzMlcyPjNizszN	Mn3jV2FPT0WU
HCC1143	MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfFdYNKSzVyPUGzMlc1OzdizszN	MXTTRW5ITVJ?
REH	NX63WVlwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTF\|Lki5PFIh\|ryP	NELsfWpUSU6JRWK=
CESS	NIH3OoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vCdWlEPTB;MUOuPVQ5QSEQvF2=	M3;WWnNCVkeHUh?=
EFM-19	Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2j4UGlEPTB;MUSuNVEyOiEQvF2=	M1uyPHNCVkeHUh?=
U031	NELoNphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\mRWlEPTB;MUSuOFA5PSEQvF2=	NWP0OGpVW0GQR1XS
ES1	NHm4XFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TZU2lEPTB;MUSuOFg2OSEQvF2=	MXnTRW5ITVJ?
HSC-3	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmmyTWM2OD1zND62NlE2KM7:TR?=	NIK2V5lUSU6JRWK=
LOXIMVI	NX2wNWVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4myWmlEPTB;MUSuO\|A3QCEQvF2=	M17pUXNCVkeHUh?=
A388	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFr4RpJKSzVyPUG0Mlc2PTZizszN	MkOwV2FPT0WU
KP-N-YS	MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTF2Lke3N{DPxE1?	M{XyfXNCVkeHUh?=
Capan-2	M1q2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jncWlEPTB;MUSuO\|g3KM7:TR?=	MlzCV2FPT0WU
SKG-IIIa	M37WPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjQVVJbUUN3ME2xOE45QDZ{IN88US=>	Mn;4V2FPT0WU
HEL	NGLVfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLQOGZUUUN3ME2xOE45QTl5IN88US=>	NVrNOHMyW0GQR1XS
BEN	M3vXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTF2Lkm3OlYh\|ryP	MV\TRW5ITVJ?
MC116	NUfNOGc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M32yb2lEPTB;MUWuNVU6QSEQvF2=	MV;TRW5ITVJ?
IGROV-1	M1HMbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\xUGlEPTB;MUWuNlMyPyEQvF2=	NHGxc4VUSU6JRWK=
NCI-H1648	MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzWfHBKSzVyPUG1MlU{ODVizszN	MX7TRW5ITVJ?
ABC-1	NWjpcnRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHu2N2ZKSzVyPUG1MlgxOzNizszN	MnTmV2FPT0WU
EW-18	MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjKTWM2OD1zNT65PVc6KM7:TR?=	NHnVdmlUSU6JRWK=
BC-3	NFnQW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TiOWlEPTB;MU[uNFU3OiEQvF2=	MV7TRW5ITVJ?
NCI-H1437	M2nJZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37nS2lEPTB;MU[uNFY3PyEQvF2=	MknEV2FPT0WU
SCC-15	MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF36cpBKSzVyPUG2MlI5OjVizszN	M{XRcXNCVkeHUh?=
TT	NEPoSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXf5VHRHUUN3ME2xOk42QDh6IN88US=>	MnPuV2FPT0WU
KINGS-1	NGHuR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPSZ\|BsUUN3ME2xOk45Ojd\|IN88US=>	M{PLU3NCVkeHUh?=
C32	NWrjZ\|JiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nGPGlEPTB;MU[uPVcyPyEQvF2=	NWnPc5lVW0GQR1XS
SBC-5	MmPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Moi2TWM2OD1zNz6xOFc6KM7:TR?=	M{[2fHNCVkeHUh?=
NB1	NXHXcYlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX:5WGE3UUN3ME2xO{4{OTh6IN88US=>	MWTTRW5ITVJ?
EB-3	NGDLVJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTF5LkW3OkDPxE1?	NGT2TGxUSU6JRWK=
NCI-H748	NHrBc45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\wOplqUUN3ME2xO{44ODN3IN88US=>	M4XCTHNCVkeHUh?=
IST-SL1	NXLFZZpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFv0TlhKSzVyPUG3Mlc2OjZizszN	MUXTRW5ITVJ?
WM-115	NGnDUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnHZ29iUUN3ME2xO{45ODh3IN88US=>	NWn2d2JZW0GQR1XS
NCI-H226	M17XSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETQeWxKSzVyPUG3Mlk2PDZizszN	M4npS3NCVkeHUh?=
CAL-33	NEDhclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\LTWM2OD1zOD6yO\|gyKM7:TR?=	NFvte4hUSU6JRWK=
SCC-4	NIPXUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTF6LkOyNlkh\|ryP	NGTnbVNUSU6JRWK=
RMG-I	NY\YXWlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPvOZN{UUN3ME2xPE43QTR5IN88US=>	M{PaUHNCVkeHUh?=
KOSC-2	NYj2cnhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHudHlCUUN3ME2xPE44PzR4IN88US=>	NXPISlFoW0GQR1XS
A2058	NGnXU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPHTWM2OD1zOD64NlU2KM7:TR?=	M{fYZ3NCVkeHUh?=
HCC70	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\iOVVKSzVyPUG5MlM5QTRizszN	NHfMWmtUSU6JRWK=
C2BBe1	MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGG1XYFKSzVyPUG5MlQyPDhizszN	MYTTRW5ITVJ?
NCI-H650	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3SzO2lEPTB;MUmuOVg6QSEQvF2=	MYXTRW5ITVJ?
CAL-72	NUixSVhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfL[FhKSzVyPUG5MlY4OzdizszN	MkXCV2FPT0WU
L-363	NXjkRmQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnC[YJKSzVyPUKwMlAzOTJizszN	MXnTRW5ITVJ?
SNU-423	NGjmTpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfDVldIUUN3ME2yNE4yODR\|IN88US=>	NVvWdI9yW0GQR1XS
PLC-PRF-5	M2\qOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nnU2lEPTB;MkCuN\|kxPiEQvF2=	M2LGRXNCVkeHUh?=
SW1463	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfIUppIUUN3ME2yNE41PTJ3IN88US=>	NVe3blVWW0GQR1XS
769-P	NEHHV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE[4dYtKSzVyPUKwMlY4PjlizszN	MnPBV2FPT0WU
DMS-79	M1zocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7PNJpKSzVyPUKwMlg1QSEQvF2=	MkXmV2FPT0WU
Saos-2	NEj2WGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPFRlVKSzVyPUKwMlk2PTZizszN	MmnGV2FPT0WU
CHP-126	NV21XYUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37rW2lEPTB;MkGuOFQ3OiEQvF2=	NYrmbWxCW0GQR1XS
SW837	NXXmUYJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nVb2lEPTB;MkGuOFk{QSEQvF2=	M4riWHNCVkeHUh?=
SHP-77	NFnYO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH71XXhKSzVyPUKxMlYyOjJizszN	Mmj0V2FPT0WU
DB	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHETWM2OD1{MT62NVQzKM7:TR?=	MXzTRW5ITVJ?
ES5	Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVH6UoFqUUN3ME2yNU43QDZ2IN88US=>	MlzFV2FPT0WU
COR-L23	NGnmb2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTJzLkiwOVEh\|ryP	MXfTRW5ITVJ?
KU-19-19	NHf3cItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rVXWlEPTB;MkGuPFk5OiEQvF2=	MYLTRW5ITVJ?
T84	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1H2XGlEPTB;MkGuPVgyQSEQvF2=	M{jiWHNCVkeHUh?=
NCI-H630	M1PtRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjCTWM2OD1{Mj61N\|Y{KM7:TR?=	NXPKTGZvW0GQR1XS
LU-165	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVraTlJyUUN3ME2yNk42PTRizszN	NGjPcI9USU6JRWK=
COLO-792	NIjiU\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETReYxKSzVyPUKyMlcyOTFizszN	MXTTRW5ITVJ?
CAL-62	M3XUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTJ{Lke1NVch\|ryP	M2L3ZXNCVkeHUh?=
HCE-T	NYrBZmg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTJ{Lki2NFYh\|ryP	MUXTRW5ITVJ?
BB65-RCC	NXrsOIF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjRR5ZuUUN3ME2yN{4xOzR2IN88US=>	MmP1V2FPT0WU
SiHa	NYXYU4FLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLjTWM2OD1{Mz6zPVY5KM7:TR?=	NIrJcHVUSU6JRWK=
NCI-H2081	NHP1W5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXTTWM2OD1{ND6wOlQyKM7:TR?=	NVTTZoxWW0GQR1XS
U251	NUTO[ldFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHvdWZYUUN3ME2yOE4xPjZ6IN88US=>	M1WzdHNCVkeHUh?=
LoVo	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTJ2LkmyPFIh\|ryP	NFTFb2xUSU6JRWK=
GCIY	M4[3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\MZYpKSzVyPUK1MlI5PzdizszN	MWfTRW5ITVJ?
NUGC-3	NFTWXpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1ezT2lEPTB;MkWuN\|MyPiEQvF2=	Mn\HV2FPT0WU
LNCaP-Clone-FGC	M4TnOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTJ3LkO0PVgh\|ryP	MmLJV2FPT0WU
PA-1	M{jnfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn64TWM2OD1{NT62PFM{KM7:TR?=	NF7mXW5USU6JRWK=
OE33	Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2KwVmlEPTB;MkWuOlg2OyEQvF2=	M2L5VXNCVkeHUh?=
HT-29	NXfIS4N4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTJ3Lke4O\|kh\|ryP	MW\TRW5ITVJ?
RCM-1	M1HyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1njeGlEPTB;MkWuPVY2PiEQvF2=	MnnwV2FPT0WU
NCI-H1522	NGrLO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzndpJKSzVyPUK1Mlk6OTFizszN	MV\TRW5ITVJ?
LB373-MEL-D	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojuTWM2OD1{Nj6xO\|A5KM7:TR?=	NWLqNGtFW0GQR1XS
NCI-H1436	NXrOd4pQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETEW4JKSzVyPUK2MlI4OzhizszN	NGnkc25USU6JRWK=
COLO-824	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fQNmlEPTB;Mk[uOFAxOiEQvF2=	NWnFc4tJW0GQR1XS
CP50-MEL-B	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\tTWM2OD1{Nj61Olc2KM7:TR?=	MYHTRW5ITVJ?
EGI-1	NVHJbXc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1z0NmlEPTB;MkeuNlY6QCEQvF2=	NG\MVmFUSU6JRWK=
LAN-6	M1zNVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjLTppqUUN3ME2yO{4{PTl6IN88US=>	MXjTRW5ITVJ?
GAK	NHXJV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjDTWM2OD1{Nz60NlI2KM7:TR?=	NULsbI9uW0GQR1XS
MDA-MB-175-VII	NFvUVYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTJ5LkWwOVMh\|ryP	NF\wToRUSU6JRWK=
JVM-2	NWnhbXFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFq1flZKSzVyPUK3MlY3OjJizszN	Mn65V2FPT0WU
UACC-257	NIHFOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rCdmlEPTB;MkeuOlg4QCEQvF2=	MYfTRW5ITVJ?
SW1783	M2XV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTTVFhKSzVyPUK3Mlc4QDNizszN	M3vRWnNCVkeHUh?=
HT-3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PMcWlEPTB;MkiuNlE3PiEQvF2=	NF;0bodUSU6JRWK=
RL	NWXPW4ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTJ6LkW5NVEh\|ryP	MYXTRW5ITVJ?
TK10	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTJ6Lk[1N\|Uh\|ryP	NF\XVWlUSU6JRWK=
HT55	MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{S3PWlEPTB;MkmuNFU3PSEQvF2=	NWftdWdPW0GQR1XS
BT-20	MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTCbItKSzVyPUK5MlA2QDZizszN	Mn\mV2FPT0WU
TGBC24TKB	NHnCWGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvnUXhKSzVyPUK5MlE5OzFizszN	M1i0OHNCVkeHUh?=
HSC-2	MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3PTWM2OD1{OT6zNFAyKM7:TR?=	NFHJNnZUSU6JRWK=
COLO-205	M1LXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHuyUFZKSzVyPUK5MlM6PDRizszN	NHjNZo5USU6JRWK=
GT3TKB	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEj1UGtKSzVyPUK5MlY5PzdizszN	MofrV2FPT0WU
T47D	MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTJ7Lki1PFIh\|ryP	MVTTRW5ITVJ?
OMC-1	NUXpOGR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXe3UnNMUUN3ME2zNE4yQTF7IN88US=>	NFf2[XFUSU6JRWK=
PFSK-1	NF7aPGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfRUJVyUUN3ME2zNU4zPjV7IN88US=>	M2rWV3NCVkeHUh?=
JEG-3	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXjTWM2OD1\|MT6zOVYyKM7:TR?=	NWTWeYtQW0GQR1XS
RD	MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvNV5VKSzVyPUOxMlUyOTVizszN	NYXVO5cxW0GQR1XS
NCI-H64	NWLYPJlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTBN4RnUUN3ME2zNk41OTd7IN88US=>	MnvaV2FPT0WU
DMS-114	M1;0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHQNG1KSzVyPUOyMlQyQDJizszN	NF;Kbm1USU6JRWK=
NCI-H661	MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HhOGlEPTB;M{KuOlUxOSEQvF2=	NH34NnFUSU6JRWK=
CAL-148	MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrTc2ZKSzVyPUOyMlY3PjVizszN	M{npZ3NCVkeHUh?=
HuP-T3	MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;YTWM2OD1\|Mj65N\|M5KM7:TR?=	MXPTRW5ITVJ?
ES4	MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrmPFhlUUN3ME2zN{4yPzB3IN88US=>	M{nGT3NCVkeHUh?=
Ca9-22	NUfORXcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTN\|LkS2NFEh\|ryP	NFTWTWNUSU6JRWK=
LP-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XQ[mlEPTB;M{SuNFkh\|ryP	NInsNmJUSU6JRWK=
AU565	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XKRmlEPTB;M{SuOVA3QSEQvF2=	M3zvRnNCVkeHUh?=
MDA-MB-453	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTN3LkG0NlYh\|ryP	M{nCWHNCVkeHUh?=
SNU-C1	MmHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjvTWM2OD1\|NT6xO\|Eh\|ryP	MUXTRW5ITVJ?
SW13	NHTG[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2[xOWlEPTB;M{WuOFA4PiEQvF2=	NHzCUJpUSU6JRWK=
NCI-H2122	M4rBXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4DJTmlEPTB;M{WuOVU6QCEQvF2=	MlPLV2FPT0WU
NCI-H1395	M3;BXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknxTWM2OD1\|NT62OlkyKM7:TR?=	MYLTRW5ITVJ?
J-RT3-T3-5	M2H6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnu0TWM2OD1\|Nj6wNlk1KM7:TR?=	NX75cmVPW0GQR1XS
COR-L279	MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTN4LkG5PFEh\|ryP	NWr1SG5qW0GQR1XS
ATN-1	MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkD6TWM2OD1\|Nj64OVE3KM7:TR?=	NGjoPIVUSU6JRWK=
HCC2998	NXXaSJh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\uWnZTUUN3ME2zOk45PTdzIN88US=>	MnjQV2FPT0WU
UM-UC-3	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPGTWM2OD1\|Nj64Olc2KM7:TR?=	NU\X[GhsW0GQR1XS
DV-90	NYP6RpU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTN4LkmwOlch\|ryP	NXnacmRDW0GQR1XS
ES8	NYjaTJJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnOV2pTUUN3ME2zOk46OzF6IN88US=>	MlXjV2FPT0WU
YAPC	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2qyNGlEPTB;M{[uPVY2PCEQvF2=	MWTTRW5ITVJ?
HCC1599	NF;l[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jZSmlEPTB;M{euNVYyQCEQvF2=	NID1R4ZUSU6JRWK=
UMC-11	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1uy[mlEPTB;M{euNlUxOyEQvF2=	NYrXenlTW0GQR1XS
THP-1	NGX5V5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTN5LkK4Olgh\|ryP	MV3TRW5ITVJ?
OCUB-M	NI\CVolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYmybY1RUUN3ME2zO{4zQDlzIN88US=>	MV7TRW5ITVJ?
NCI-H1693	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmCyTWM2OD1\|Nz6zNlM{KM7:TR?=	M33GVXNCVkeHUh?=
NCI-H345	MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXvTWM2OD1\|Nz6zOlI1KM7:TR?=	NV;Oe4ZoW0GQR1XS
COLO-800	NHjzdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfsR2VKSzVyPUO3MlU3PyEQvF2=	MXPTRW5ITVJ?
COLO-320-HSR	M17X[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nsOmlEPTB;M{iuN\|Q6OiEQvF2=	MorxV2FPT0WU
NCI-H596	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2OyTmlEPTB;M{iuOFQ5QSEQvF2=	MVjTRW5ITVJ?
NCI-H187	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTN6LkezOFQh\|ryP	MlPBV2FPT0WU
ECC4	NFTaXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTN7LkC4NVQh\|ryP	M1znVnNCVkeHUh?=
KP-4	M3X3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHhcppKSzVyPUO5MlEzOzVizszN	NUDDUWM5W0GQR1XS
NCI-H2227	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI[xfYJKSzVyPUO5MlM6PDlizszN	NYTCOJYxW0GQR1XS
22RV1	M4npZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHrU5lCUUN3ME2zPU45Ozl6IN88US=>	M4jhN3NCVkeHUh?=
SAS	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIntW2tKSzVyPUSwMlA6PiEQvF2=	NVHGN4xUW0GQR1XS
PANC-10-05	Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTRyLkG4Nlgh\|ryP	NWSyWHhsW0GQR1XS
MDA-MB-468	Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Gz[mlEPTB;NECuOVM1PiEQvF2=	M1TEVXNCVkeHUh?=
RPMI-7951	NHXLUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3PTWM2OD12MT6yNFc2KM7:TR?=	MUDTRW5ITVJ?
BB49-HNC	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXtTWM2OD12MT6yNVc6KM7:TR?=	NUL1e4JjW0GQR1XS
23132-87	M2XLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NITw[2VKSzVyPUSxMlI4OzJizszN	M4PwXXNCVkeHUh?=
HCC1569	M1Tvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTRzLkK4PFUh\|ryP	NF7QTJlUSU6JRWK=
CP66-MEL	Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXIPJQ4UUN3ME20Nk4yQDh4IN88US=>	Mn\DV2FPT0WU
K-562	NIf2RoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjZTWM2OD12Mj6yPFU1KM7:TR?=	MlLzV2FPT0WU
OCI-AML2	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorCTWM2OD12Mj64PVc1KM7:TR?=	MlvIV2FPT0WU
SW756	NHHGNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\QdWlEPTB;NEOuNFM5QCEQvF2=	NH;Qe\|VUSU6JRWK=
M14	NWO5SlhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknYTWM2OD12Mz6zNVg6KM7:TR?=	MnvmV2FPT0WU
NCI-H1623	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDyTWM2OD12Mz60OlQh\|ryP	M4jhWHNCVkeHUh?=
KNS-81-FD	M3;xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\PTWM2OD12Mz63OlIh\|ryP	NF\YW4xUSU6JRWK=
TGBC1TKB	NGrGWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{ToVmlEPTB;NEOuPVA6QSEQvF2=	MkftV2FPT0WU
RERF-LC-MS	MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnNPWZvUUN3ME20N{46OjhzIN88US=>	NX;odWZ7W0GQR1XS
PC-3	NHHNZ2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTR2LkSzOFch\|ryP	NGP5SpNUSU6JRWK=
HuP-T4	NYfxdY1iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrxVZhKSzVyPUS0MlQ1PzRizszN	NEXVNmpUSU6JRWK=
NCI-H510A	NFHWfolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzZTWM2OD12ND63NFgh\|ryP	NH\lbo9USU6JRWK=
LB2518-MEL	M1frTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DVdWlEPTB;NESuO\|k{PyEQvF2=	NETzeYZUSU6JRWK=
TE-5	NWPENWpFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\0TWM2OD12NT65OVgyKM7:TR?=	MnfLV2FPT0WU
EW-24	NGftbVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33zOmlEPTB;NE[uNVczOyEQvF2=	MWXTRW5ITVJ?
LB647-SCLC	NWmwdHRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTR4LkKxOVUh\|ryP	NYH2N5llW0GQR1XS
NCI-H524	NUPwR\|lwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDVTWM2OD12Nj63NVg2KM7:TR?=	NHToNWxUSU6JRWK=
EW-11	NX\UeHNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTR4LkmzO\|Mh\|ryP	MkjEV2FPT0WU
KALS-1	NV;nW49PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTR5LkKwOlYh\|ryP	NELUbVlUSU6JRWK=
BT-474	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XaeGlEPTB;NEeuOFIyPiEQvF2=	Mk\5V2FPT0WU
SK-N-AS	MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHpTWM2OD12Nz64PFgh\|ryP	NH3qRnFUSU6JRWK=
HCC2157	NFTGN4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\2TWM2OD12OD6wO\|Yh\|ryP	NF\TfGpUSU6JRWK=
HCC1954	MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLsTWM2OD12OD6xO\|A1KM7:TR?=	MlrCV2FPT0WU
FADU	MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;FTGlEPTB;NEiuN\|A{OSEQvF2=	MWTTRW5ITVJ?
S-117	NFz5No5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTR6LkO4NVUh\|ryP	NEHmbJpUSU6JRWK=
LS-1034	M1O1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzETWM2OD12OD63NFY4KM7:TR?=	NIfGSFBUSU6JRWK=
CAMA-1	NX[yZYt1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTR7LkW1OFMh\|ryP	M3XVZ3NCVkeHUh?=
LU-134-A	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\RTWM2OD12OT64NFg2KM7:TR?=	NUjONYxoW0GQR1XS
NCI-H1838	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXKOWU5UUN3ME20PU45ODh5IN88US=>	NUDCO3BJW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pSrc / Src / pPlcg / Plcg / pStat5 / Stat5 ; PubMed: 22781593 Leukemia In (B) inhibition of Src, Plcg and Stat5 was seen in MLNAF cell lines treated with Ponatinib; ZNF112 expresses ZMYM2–FGFR1, CEP2A and CEP5A cells express CEP110–FGFR1 and BBC2 expresses BCR–FGFR1. pFGFR1(pY20) / FGFR1; PubMed: 22781593 Leukemia Western blot analysis, using various antibodies specific for downstream targets of FGFR1, demonstrates that Ponatinib inhibits the activation of Plcg and Src as a result of inhibiting the FGFR1 fusion kinase in human KG1 cells. cleaved caspase-3 / cleaved caspase-7 / BAX / Bcl-2; PubMed: 30959969 Molecules Western blot analysis of cleaved caspase-3, cleaved caspase-7, Bax, Bcl-2, and β-Tubulin (control) in treated cells. p-Rb(S807/811) / Rb / CDK4 / CDK6 / Cyclin D1 / CDK2 / Cyclin E1; PubMed: 30959969 Molecules Western blot analysis of Rb/p-Rb, CDK4, CDK6, Cyclin D1, CDK2, Cyclin E1, and β-Tubulin (control) in the SK-Hep-1 and SNU-423 cells treated with ponatinib. RAD51; PubMed: 30959969 Molecules The effect of ponatinib on the concentration of Rad51 in SK-Hep-1 and SNU-423 cells. p-MEK / MEK / p-ERK / ERK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Mek and Erk. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. c-Jun / p-JNK(T183/Y185) / JNK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of JNK and c-Jun. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-p38 MAPK / p38 MAPK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of p38. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-JAK2 / JAK2 / p-STAT3 / STAT3; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Jak2, and Stat3. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. PI3K p85 / p-PI3K / p-PDK1 / PDK1 / p-mTOR / mTOR; PubMed: 30959969 Molecules Effects of ponatinib on the protein concentration and phosphorylation of PI 3-kinase, PDK1, Akt, and mTOR in HCC cells. p-PDGFRα / PDGFRα; PubMed: 24472312 Mol Cancer Ponatinib inhibited phosphorylation of PDGFRα in a concentration-dependent manner. EOL-1 and BaF3-WT or -T674I FIP1L1-PDGFRα cells were exposed to escalating concentrations of ponatinib for 24 h. PARP / Caspase-3 / Active Caspase-3; PubMed: 24472312 Mol Cancer The concentration- (for 24 h) and time-dependent (1 nM for EOL-1, 300 nM for BaF3-WT and -T674I FIP1L1-PDGFRα cells) cleavage of PARP and caspase-3 triggered by ponatinib was analyzed by immunoblotting. AIF / Cyto C ; PubMed: 24472312 Mol Cancer Ponatinib elicited release of AIF and cytochrome c into the cytosol. Cells were treated with 1 nM ponatinib for the indicated durations and the cytosolic fraction was extracted with digitonin buffer. Levels of AIF and Cytochrome c (Cyto c) were detected by immunoblotting. Mcl-1 / Survivin / Bcl-Xl / XIAP / Bax / Bcl-2 / Bim; PubMed: 24472312 Mol Cancer Immunoblotting of apoptosis-related proteins in CEL cells after treatment for 24 h. β-catenin ; PubMed: 24472312 Mol Cancer Ponatinib concentration-dependently lowered β-catenin. EOL-1 cells were incubated with ponatinib for 24 h, and cytoplasmic and nuclear extracts were determined by immunoblotting. β-catenin; PubMed: 24472312 Mol Cancer Analysis of β-catenin localization. EOL-1 cells were pretreated with 1 nM ponatinib for 24 h, immunofluorescence analysis was performed with anti-β-catenin. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). ABL; PubMed: 19878872 Cancer Cell In vitro [γ-32P]-ATP autophosphorylation of full-length (A) ABL or (B) ABLT315I kinase treated with AP24534, imatinib, nilotinib, or dasatinib. After incubation of tyrosine-dephosphorylated enzyme with the indicated inhibitor in the presence of [γ-32P]-ATP and separation by SDS-PAGE, signal intensity was measured by autoradiography.	22781593 30959969 24472312 19878872
Growth inhibition assay	Cell viability; PubMed: 30174789 Oncotarget (A) Effect of Ponatinib on basal viability of HUVECs. The cells were treated with Ponatinib at indicated concentrations or 0.1% DMSO (vehicle control) for 24 h.	30174789

体内研究

Ponatinib抑制取自FLT3-ITD阳性AML病人的原代白血病细胞，而不抑制表达阴性FLT3的AML病人的白血病细胞。^[3]

激酶实验：^[1]	- 合并激酶实验: 通过同质时间分辨荧光共振能量转移法(TR-FRET)，使用纯化的人类野生型ABL激酶，T315I突变型ABL激酶，及生物素化的磷酸激酶底物肽: 生物素-EKKMAAEAIYAAPFAK-NH2，测定野生型ABL和T315I突变型ABL活性的抑制激酶反应在全LANCE激酶buffer (LKB)中进行，LKB包括20 mM NaHEPES（pH 为7.4）, 0.1 mg ⁄ mL BSA, 1 mM ATP, 10 mM MgCl₂, 及0.41 mM DTT，在提前用1% BSA（溶于PBS）包被的96孔板上4^oC下过夜。用于激酶反应，Ponatinib稀释物和野生型ABL, T315I突变型ABL (40 pM), 及底物肽(50 nM), 在室温下温育1小时（T315I突变型ABL）或2小时（野生型ABL）。加入15 nM 抑制剂, 6 nM 铕标记的磷酸酪氨酸抗体（磷酸化位点在第66为酪氨酸上），及60 nM 别藻蓝素标记的链酶亲和素，终止反应。实验板在室温下黑暗温育20分钟，使用Wallac Victor2V读数器读取615和665nm处的荧光值。在孔中数据平均值中插入抑制剂的3倍连续稀释液，再读取665nm处荧光值，计算IC50值。
细胞实验：^[1]	- 合并 Cell lines: Ba ⁄ F3细胞 Concentrations: 0-625 nM, 和0-10 µM Incubation Time: 72小时 Method: Ba/F3细胞系按每孔4×10³个细胞分布在96孔板上(4×10³)，和梯度浓度Ponatinib温育72小时。Ponatinib浓度范围为: 0-625 nM 作用于表达BCR-ABL细胞，0-10 µM 用于测定BCR-ABL阴性细胞。使用MTS实验测定细胞增殖，取三次平行实验平均值测定IC50值。 (Only for Reference)
动物实验：^[3]	- 合并 Animal Models: 皮下植入MV4-11细胞移植瘤(1×10⁷，50%基质胶中) 的雌性CB.17 SCID鼠 Formulation: 25 mmol/L柠檬酸盐缓冲液(pH 为2.75) Dosages: 每天处理一次，持续4周 Administration: 口服饲喂处理 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	30 mg/mL (56.33 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 1% CMC Na	30mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Ponatinib (AP24534) SDF

分子量	532.56
化学式	C₂₉H₂₇F₃N₆O
CAS号	943319-70-8
储存条件	3年 -20°C粉状
储存条件	2年 -80°C 溶于溶剂
别名	N/A

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04070443	Not yet recruiting	Drug: Ponatinib\|Drug: Imatinib	Philadelphia Chromosome Positive CML\|BCR-ABL Positive Chronic Myelogenous Leukemia	Centre Leon Berard	October 1 2019	Phase 2
NCT03934372	Not yet recruiting	Drug: Ponatinib	Acute Myeloid Leukemia\|Accelerated Phase Chronic Myeloid Leukemia\|Blast Phase Chronic Myeloid Leukemia\|Chronic Phase Chronic Myeloid Leukemia\|Acute Lymphoblastic Leukemia\|Acute Lymphocytic Leukemia\|Leukemia\|Lymphoma\|Solid Tumors	Incyte Biosciences International Sàrl\|Incyte Corporation	October 25 2019	Phase 1\|Phase 2
NCT03895671	Recruiting	Drug: Ponatinib\|Drug: Azacitidine	CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE\|CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS	Versailles Hospital	June 19 2019	Phase 2
NCT03690115	Recruiting	Drug: Ponatinib 30 MG	Leukemia Myeloid Acute	Versailles Hospital	December 12 2018	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
Is the pre-solubilized inhibitor suitable for in vivo whole animal studies? Whether the solvent contains any non-DMSO stabilizer?
回答：
Our 10mM Ponatinib in DMSO solution is in pure DMSO and there is not other stabilizer added. You can use it for animal study. The vehicle we suggest for Ponatinib is: 30% PEG400/0.5% Tween80/5% Propylene glycol. It is a milky suspension used for oral gavage.

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

选择性强的Bcr-Abl抑制剂

Nilotinib (AMN-107) : Bcr-Abl-selective, IC50<30 nM.
活性最高的Bcr-Abl抑制剂

GZD824 : Bcr-Abl(WT), IC50=0.34 nM; Bcr-Abl(T315I), IC50=0.68 nM.
FDA批准的Bcr-Abl抑制剂

Dasatinib : Approved by FDA for CML and Ph+ ALL.
最新的Bcr-Abl抑制剂

GZD824 : Orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

研究领域

产品类型

Ponatinib (AP24534)

客户使用Selleck该产品发表文献83篇：

产品安全说明书

Bcr-Abl抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Ponatinib (AP24534) SDF

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

技术支持

常见问题及建议解决方法

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

相关Bcr-Abl产品